Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials

BACKGROUND: Controlled studies and observational studies have shown that sodium-glucose cotransporter type 2 inhibitors (SGLT-2i) are beneficial for the survival of patients with heart failure (HF). However, it is unclear whether SGLT-2i can provide benefit in patients with other cardiovascular dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Caiyun, Lin, Meimei, Chen, Yan, Xu, Haiting, Yan, Lingqun, Dai, Hengfen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063441/
https://www.ncbi.nlm.nih.gov/pubmed/33888126
http://dx.doi.org/10.1186/s12933-021-01272-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063441/
https://www.ncbi.nlm.nih.gov/pubmed/33888126
http://dx.doi.org/10.1186/s12933-021-01272-z

Ejemplares similares